World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
63712
World Ranking
14330
National Ranking
550

Overview

Camillo Porta is affiliated with the University of Bari Aldo Moro in Italy and specializes in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research spans various subfields, including Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research, and Surgery.

The scientist's research focuses primarily on cancer-related topics. Notable areas of study include Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Renal and related cancers, Economic and Financial Impacts of Cancer, Bladder and Urothelial Cancer Treatments, and Pancreatic and Hepatic Oncology Research.

Camillo Porta has contributed to multiple recent papers in high-impact medical journals. Significant publications include:

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma, 2021, New England Journal of Medicine
  • Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma, 2021, New England Journal of Medicine
  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial, 2020, ESMO Open
  • Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial, 2022, The Lancet Oncology
  • Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival, 2021, JAMA Network Open

The scientist frequently publishes research in several key oncology journals. The most common venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • ESMO Open
  • Clinical Genitourinary Cancer
  • Frontiers in Oncology

Collaboration is a notable aspect of their research activity. Camillo Porta regularly coauthors papers with other researchers, including Mimma Rizzo, Toni K. Choueiri, Robert J. Motzer, Giuseppe Procopio, and Matteo Santoni.

Best Publications

  • Sorafenib in Advanced Hepatocellular Carcinoma

    Josep M. Llovet;Sergio Ricci;Vincenzo Mazzaferro;Philip Hilgard

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    Robert J Motzer;Bernard Escudier;Stéphane Oudard;Thomas E Hutson

  • Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    B. Escudier;C. Porta;M. Schmidinger;N. Rioux-Leclercq

  • Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

    Robert J. Motzer;Bernard Escudier;Stephane Oudard;Thomas E. Hutson

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    Robert Motzer;Boris Alekseev;Sun Young Rha;Camillo Porta

  • Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

    Toni K. Choueiri;Thomas Powles;Mauricio Burotto;Bernard Escudier

  • Targeting PI3K/Akt/mTOR Signaling in Cancer.

    Camillo Porta;Chiara Paglino;Alessandra Mosca

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

    Jordi Bruix;Jean Luc Raoul;Morris Sherman;Vincenzo Mazzaferro

  • Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Osvaldo Arén Frontera

  • Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

    Martin E Gore;Cezary Szczylik;Camillo Porta;Sergio Bracarda

  • Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study

    Armando Santoro;Lorenza Rimassa;Ivan Borbath;Bruno Daniele

  • Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study

    Bernard Escudier;Camillo Porta;Petri Bono;Thomas Powles

  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

    Laurence Albiges;Nizar M. Tannir;Mauricio Burotto;David McDermott;David McDermott

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.

    F Massari;M Santoni;C Ciccarese;D Santini

  • Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nolatrexed or Doxorubicin

    Robert G. Gish;Camillo Porta;Lucian Lazar;Paul Ruff

  • Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

    Lorenza Rimassa;Eric Assenat;Markus Peck-Radosavljevic;Marc Pracht

  • Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

    Robert John Motzer;Camillo Porta;Nicholas J Vogelzang;Cora N Sternberg

Frequent Co-Authors

Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Toni K. Choueiri
Toni K. Choueiri Harvard University
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Thomas Powles
Thomas Powles Queen Mary University of London
Ugo De Giorgi
Ugo De Giorgi The University of Texas MD Anderson Cancer Center
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Thomas E. Hutson
Thomas E. Hutson Texas Oncology
Cora N. Sternberg
Cora N. Sternberg Cornell University
Alain Ravaud
Alain Ravaud University of Bordeaux

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways in healthcare is becoming increasingly popular, especially for those seeking flexible or accelerated routes to a rewarding career. If you’re aiming to begin working quickly, consider the fastest lpn program, which can help you launch a career as a Licensed Practical Nurse in less time by offering convenient online options.

For those interested in mental health, advancing professionally through online msn pmhnp programs allows you to specialize as a Psychiatric Mental Health Nurse Practitioner, often with flexible schedules to balance with work commitments.

If patient care isn't your primary focus, a healthcare administration degree online can prepare you for leadership roles within hospitals, clinics, or other health systems. You’ll gain essential business and management skills needed in today’s healthcare landscape.

Interested in even more advanced roles? Consider the masters in healthcare administration cost to find affordable graduate programs that can propel your career in healthcare management.

Best Scientists Citing Camillo Porta

Trending Scientists

Recently Published Articles